Quest Diagnostics, the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx ...

Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to ...

Physicians in the United States may order the PD-L1 IHC 28-8 pharmDx test service directly from Quest Diagnostics. As one of the first labs to have the assay validated and available through early ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced the launch of a new laboratory blood test designed to ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with cognitive decline.

Quest Diagnostics is rolling out an antibody test consumers can order online before ever going to the doctor's office.

Quest Diagnostics unveiled a first-to-market blood test for consumers that helps assess the potential risk of developing Alzheimer’s disease.

The Quest Diagnostics Cervical Cancer TERC test is based on the human telomerase RNA component (TERC) gene marker under a nonexclusive patent license from the National Institutes of Health (NIH).

The U.S. Food and Drug Administration (FDA) on Saturday reissued an emergency use authorization to Quest Diagnostics to authorize a coronavirus test with pooled samples.

Quest Diagnostics on Thursday announced it has launched a new, FDA-authorized at-home COVID-19 test kit. Quest Diagnostics provided this photo of its new at-home test kit.